Drug intelligence / Profile preview

lactobacillus plantarum LPL28

Development stage
Unknown
Lead developer
Jinqi Biological
Modality
Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration
Oral
01

Overview

**Lactobacillus plantarum LPL28** is a specific probiotic strain of Lactobacillus plantarum, originally isolated from fermenting soybeans in 2011[3]. It is characterized by its beneficial effects on oral health, notably in reducing *Streptococcus mutans*, improving oral microbial flora, increasing secretory IgA in saliva, and supporting the immune response[3][4][6]. LPL28 is distinguished for its strong tolerance to acidic and bile environments, indicating robust survivability through the gastrointestinal tract[3]. Clinical research highlights its applications as a food additive and in oral lozenge formulations to promote oral health, relieve gastrointestinal symptoms, and decrease the incidence of oral infections, constipation, gastroesophageal reflux, and upper respiratory tract symptoms[2][4][6]. The strain has demonstrated superior antipathogenic and bactericidal activities against major oral pathogens (*S. mutans*, *A. actinomycetemcomitans*, *P. gingivalis*) in both postbiotic (heat-killed and fermentation product) and viable forms[2]. Its mechanism of action involves microbiome modulation, pathogen inhibition by antimicrobial metabolite production, and immunostimulation.

Other names
LPL28LPL-28LPL 28L. plantarum LPL28

Beyond the preview

Go deeper on lactobacillus plantarum LPL28.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on lactobacillus plantarum LPL28.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call